In a report published Friday, BofA Merrill Lynch analyst Olivia Tong downgraded *Nu Skin Enterprises* (NYSE: NUS) from Buy to Neutral, with a $94.00 price objective.
According to the report, earlier this week, an article in China's People's Daily suggested that NUS was engaging in improper selling practices amongst other things. Reported by Benzinga.com 10 hours ago.
According to the report, earlier this week, an article in China's People's Daily suggested that NUS was engaging in improper selling practices amongst other things. Reported by Benzinga.com 10 hours ago.